Nurix Therapeutics (NRIX) Stock Falls -35% Over 30 Days After Sanofi Termination

Key Takeaways

• Nurix Therapeutics (NRIX) shares fell roughly 35% over the trailing 30 days, sliding from a closing price near $23.67 to about $15.39, driven chiefly by a partner decision on one of its drug programs.
• The decline accelerated sharply in early November, when the stock dropped approximately 38% in after-hours trading following Sanofi's decision to terminate the STAT6 degrader program.
• The termination removes future development, regulatory, and commercial milestone payments and royalties that Nurix had been eligible to receive for the oral candidate SAR448272.
• Nurix retained roughly $1.1 billion in cash, cash equivalents, and marketable securities as of August 31, 2026, with a cash runway into the second half of 2029.
• The company's broader pipeline remains intact, anchored by the BTK degrader bexobrutideg being co-developed with Roche, along with NX-1607 and a Gilead-partnered IRAK4 degrader.

Company Background and Strategic Positioning

Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation, an approach that uses small molecules to direct the body's E3 ligase system against disease-causing proteins. This platform targets oncology as well as autoimmune and inflammatory conditions, offering a mechanism that differs from traditional inhibitors. Its lead asset, bexobrutideg (NX-5948), is an oral, brain-penetrant BTK degrader. In mid-2026 the company entered a global collaboration with Roche (RHHBY) valued at roughly $2.3 billion, including a $700 million upfront payment. The pipeline also features NX-1607, an oral CBL-B inhibitor, and an IRAK4 degrader partnered with Gilead (GILD). I checked comparable names in the space using Tickeron’s AI Screener to place these partnerships in context.

Recent Price Action: 30-Day and Quarterly Moves

Over the past 30 days NRIX declined about 35%, moving from near $23.67 down to roughly $15.39. Most of the drop occurred in one session in early November after the Sanofi news, with shares falling around 38% in after-hours trading before settling in the low-to-mid teens. On a quarterly basis the picture is comparable yet more layered. Shares stood near $27 three months earlier, implying a decline of about 43% over that window, though much of it traces to the November event. Earlier in the quarter the stock had climbed toward the high-$20s on collaboration momentum before pulling back and then recovering modestly into October.

Key Driver Behind the 30-Day Decline

The primary catalyst arrived on November 3, 2026, when Sanofi (SNY) notified Nurix of its decision to end the Phase 1 trial of SAR448272, an oral STAT6 degrader, and terminate the program. Because the asset fell under the existing collaboration, the move eliminated associated future milestone payments and royalties that could have totaled hundreds of millions of dollars. The reaction went beyond the loss of one early-stage candidate. As a pre-revenue company, Nurix depends on collaboration economics, and the termination reduced near-term visibility into non-dilutive funding. Management noted that the broader Sanofi partnership continues and that cash runway guidance into the second half of 2029 remains unchanged.

Quarterly Performance Context

Positive pipeline updates shaped much of the earlier quarterly trend. The Roche collaboration expansion and the start of the registrational Phase 3 DAYBreak CLL-306 trial for bexobrutideg in relapsed or refractory CLL helped lift shares toward $28 by late August. A late-September consolidation followed, then a modest October recovery kept attention on the BTK franchise. The November Sanofi termination reversed those gains, leaving the stock lower over the full quarter despite constructive developments for most of the period. I reviewed the price history with Tickeron’s AI Daily Buy/Sell Signals to see how the moves aligned with broader sector patterns.

Key Factors to Monitor Going Forward

Attention will center on bexobrutideg and its progress under the Roche collaboration, including upcoming data across oncology, immunology, and neurology. Updates on NX-1607, the Gilead-partnered IRAK4 program, and any additional milestones from remaining partnerships will also matter. Quarterly financial reports and cash runway commentary remain important, along with any news on other Sanofi-licensed assets. Sector sentiment toward clinical-stage biotech and competitive developments in protein degradation will influence the stock as well. Binary outcomes in trials or further partnership decisions continue to represent meaningful risks.

AI Tools in Biotech Research

When evaluating names like NRIX, I sometimes cross-reference technical setups with Tickeron’s AI Trend Prediction Engine. The platform aggregates pattern data and historical analogs across thousands of tickers, which can offer an additional layer of context alongside clinical and partnership updates. It is one of several resources I consult to stay objective during periods of elevated volatility.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Notable companies

Industry description

Market Cap

High and low price notable news

Volume